12月12日 - ** 制药商BioCryst Pharmaceuticals BCRX.O股价盘前上涨2%至7.73美元
** 美国食品和药物管理局（FDA）批准 (link) 公司为遗传性血管性水肿儿科患者开发的每日一次口服颗粒剂药物 Orladeyo
** 遗传性血管性水肿是一种遗传性疾病，会导致儿童身体的不同部位发生肿胀，包括脸部和手部。
** Orladeyo 是一种预防性疗法，旨在预防遗传性血管性水肿的发作。
** 截至上次收盘，股价累计上涨 0.8
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.